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Elevated levels of the free fatty acid palmitate are found in
the plasma of obese patients and induce insulin resis-
tance. Skeletal muscle secretes myokines as extracellular
signaling mediators in response to pathophysiological
conditions. Here, we identified and characterized the
skeletal muscle secretome in response to palmitate-in-
duced insulin resistance. Using a quantitative proteomic
approach, we identified 36 secretory proteins modulated by
palmitate-induced insulin resistance. Bioinformatics analy-
sis revealed that palmitate-induced insulin resistance in-
duced cellular stress and modulated secretory events. We
found that the decrease in the level of annexin A1, a secre-
tory protein, depended on palmitate, and that annexin A1
and its receptor, formyl peptide receptor 2 agonist, played a
protective role in the palmitate-induced insulin resistance
of L6myotubes through PKC-modulation. In mice fed with
a high-fat diet, treatment with the formyl peptide receptor 2
agonist improved systemic insulin sensitivity. Thus, we
identified myokine candidates modulated by palmitate-in-
duced insulin resistance and found that the annexin A1-
formyl peptide receptor 2 pathway mediated the insulin
resistance of skeletal muscle, as well as systemic insulin
sensitivity. Molecular & Cellular Proteomics 14: 10.1074/
mcp.M114.039651, 882–892, 2015.
The obesity epidemic has been linked to the development
of metabolic complications such as hyperlipidemia, insulin
resistance, and hypertension (1, 2). Hyperlipidemia/dyslipi-
demia involves abnormally elevated levels of lipids and/or
lipoproteins in the plasma (3, 4). Obese patients exhibit char-
acteristics of hyperlipidemia/dyslipidemia, such as abnormal
elevations in plasma free fatty acid, cholesterol, and triglyc-
eride levels, as well as a reduction in high-density lipoprotein
content (3–5). Elevated free fatty acid levels in the plasma of
obese patients play an important role in the development of
insulin resistance (6). Hence, lowering the free fatty acid level
in plasma has been shown to restore insulin sensitivity in
these patients (7). Palmitate (C16:0) is a saturated free fatty
acid found in animal plasma. It has been reported that the
concentration of plasma palmitate in obese patients is higher
than in healthy individuals (6, 8). In molecular studies, palmi-
tate has been found to induce inflammation and insulin resis-
tance in skeletal muscle cells by promoting diacylglycerol
accumulation, which in turn activates protein kinase C
(PKC)-1 and NF-B, leading to the inhibition of insulin-stim-
ulated Akt phosphorylation through insulin receptor substrate
1 (IRS1) (S307) phosphorylation and IL-6 secretion (9). Sortilin
was recently identified as a mediator of palmitate-dependent
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insulin resistance, which regulates insulin-induced glucose
transporter type 4 (GLUT4) trafficking (10). Therefore, palmi-
tate is an important hyperlipidemic/dyslipidemic component
that induces insulin resistance in skeletal muscle cells.
Skeletal muscle is thought to function as a tissue that
produces and releases cytokines called myokines (11). As
part of its extracellular signaling pathway, skeletal muscle
secretes myokines that participate in myogenesis, angiogen-
esis, and nutrient generation in response to factors such as
metabolic disorders, including insulin resistance, and exercise
(11–13). Some myokines, including IL-6, IL-8, IL-15, and fi-
broblast growth factor 21, and brain-derived neurotrophic
factor (14), are induced by exercise. Although myokines are
thought to play a critical role in the regulation of (patho)phys-
iological processes, few studies have investigated the role of
myokine in metabolism. Because skeletal muscle has a major
role in the regulation of glucose metabolism, it is important to
identify putative crucial regulators, secreted from skeletal
muscle, that modulate glucose metabolism by acting as au-
tocrine/paracrine mediators as well as endocrine mediators
(15).
Here, using an optimized secretomics approach, we per-
formed a proteomic analysis of proteins in conditioned media
from myotube cultures that were either untreated or treated
with palmitate to induce insulin resistance (16, 17). Using a
label-free quantitative analysis method, our aim was to char-
acterize the skeletal muscle secretome and to identify skeletal
muscle-derived proteins whose secretion is modulated by
palmitate-induced insulin resistance. We found 36 putative
secretory proteins modulated by palmitate-induced insulin
resistance. The secretion of annexin A1 was down-regulated
after palmitate treatment, and the annexin A1-formyl peptide
receptor 2 (FPR2) pathway played a role in palmitate-induced
insulin resistance in skeletal muscle by modulating the PKC-
pathway.
EXPERIMENTAL PROCEDURES
Cell Culture and Establishment of Insulin Resistance—Rat L6
GLUT4myc skeletal myoblast cells were used to model skeletal mus-
cle as previously described (17–21). Cells were cultured in the alpha
formulation of minimum essential medium (-MEM; Welgene, Daegu,
Korea) supplemented with 10% FBS, 2 mM glutamine, 50 g/ml
streptomycin, and 50 g/ml penicillin. Cells were provided by Dr.
Amira Klip (Hospital for Sick Children, Toronto, Canada). The cells
were passaged every second day, and confluency was maintained at
less than 80% to prevent spontaneous differentiation. To induce
differentiation, cells (4  104 cells/ml) were placed into -MEM sup-
plemented with 2% FBS for 5 days, with the medium refreshed every
48 h. The differentiation status was routinely monitored under a
microscope (LSM 510 Meta; Zeiss, Germany). Sodium-palmitate (Sig-
ma-Aldrich, St. Louis, MO) was dissolved in ethanol, heated to 50–
60 °C for 30 min, and diluted in medium containing 2% serum (2%
FBS in alpha-MEM) (22, 23). To induce palmitate-mediated insulin
resistance, L6 myotubes were incubated with 150 M of palmitate
solution for 18 h in -MEM supplemented with 2% FBS. Insulin
resistance in primary mouse skeletal muscle cells (Cell Biologics Inc.,
Chicago, IL) was induced in the same way as described above for L6
cells.
Secretome Preparation for Mass Analysis—After the L6 myotubes
were treated with palmitate, they were washed three times with
completely unsupplemented -MEM (no serum, phenol red, or anti-
biotics). Conditioned medium was prepared by incubated the myo-
tubes with unsupplemented -MEM for 5 h in a 37 °C CO2 incubator.
The conditioned medium was collected and centrifuged at 3500 rpm
for 10 min (Combi-514R; Hanil Science Industry, Incheon, Korea). The
resulting supernatant was collected and filtered using centrifugal filter
units (cat# UFC900324; Millipore, MA) to eliminate contaminants.
Dried samples filtered from the centrifugal filter units were reduced
using 10 mM DTT in 50 mM ammonium bicarbonate and then alkylated
with 100 mM iodoacetamide in 50 mM ammonium bicarbonate for
tryptic digestion. Finally, each sample was treated with trypsin (Pro-
mega, Madison, WI) for 12 h at 37 °C and dried.
Mass Analysis and Database Searching—Tryptic digests (secre-
tome peptides) were analyzed using a linear ion trap LTQ XL mass
spectrometer (MS; Thermo, San Jose, CA) interfaced with a nano-
electrospray ion source. Chromatographic separation of peptides
was achieved on a NanoLC2D system (Eksigent, Dublin, CA)
equipped with a 10-cm PicTip™ emitter with a 75-m inner diameter
(PF360–75-15-N-5; New Objective), packed in-house with a Magic
C18AQ 5-m/200-Å resin (Michrom Bioresources, Auburn, CA). Pep-
tides were loaded from a cooled (4 °C) Eksigent auto-sampler and
separated with a linear gradient of ACN/water, containing 0.1% for-
mic acid, at a flow rate of 260 nl/min. Peptide mixtures were sepa-
rated with a gradient of 2% to 40% ACN in 60 min. The analysis
method consisted of a full MS scan with a range of 300–2000m/z and
data-dependent tandem mass spectrometry (MS/MS) on the five
most intense ions from the full MS scan. The mass spectrometer was
calibrated with the proposed calibration solution according to the
manufacturer’s instructions. This study used three biological repli-
cates for each condition and two technical replicates for each bio-
logical replicate in the proteomic analysis.
The peak lists from the MS/MS data (RAW files) of the LTQ were
generated using the Trans-Proteomic Pipeline (TPP, ver. 4.6.1) (24)
and searched using a concatenated database that combined the
International Protein Index (IPI) Rat FASTA database (ver. 3.85,
39,924 sequences; 21,245,823 residues) and Bovine FASTA data-
base (ver. 3.73: 30,403 sequences; 16,412,134 residues) with the
MASCOT search engine ver. 2.2.2 (Matrix Science, London, UK),
selecting the Decoy database analysis. The MASCOT parameters
allowed for tryptic specificity of up to two missed cleavages, with
methylthio-modifications of cysteine as a fixed modification and ox-
idation of methionine as a variable modification. The LTQ search
parameters for 1, 2, and 3 ions included mass error tolerances
of 2 Da for peptide ions and 0.8 Da for fragment ions. In the
MASCOT search results, when the significance threshold was set at
0.01, the individual ions score was more than 48 (supplemental Table
S1). For the raw MASCOT search results, peptide-level (95% prob-
ability) and protein-level (99% probability) statistical validation was
performed with PeptideProphet and ProteinProphet (25) in TPP. We
removed frequently observed contaminants such as porcine trypsin,
bovine proteins, and human keratins. Proteins supported by a single
unique peptide were removed.
Label-free Quantitative Analysis Using Absolute Protein Expression
Profiling (APEX)—APEX quantitation was performed using the APEX
Quantitative Proteomics Tool ver. 1.1.0 (26). The APEX abundances of
the proteins observed with liquid chromatography (LC)-MS/MS were
calculated using the protXML files generated from the PeptidePro-
phet and ProteinProphet analyses. An FDR of 5% was chosen, with
a normalization factor of 1, which represents the total concentration
of protein molecules.
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Bioinformatic Analysis—Putative secretory proteins were selected
using three independent methods. First, proteins with the Gene On-
tology cellular components (GOCCs) of extracellular region or matrix
were selected. Second, secretory proteins were identified based on
signal sequence prediction. Following sequence extraction using an
in-house program, the resulting FASTA file was loaded onto the
SignalP 3.0 server (27) and processed using the “eukaryote” option;
the search method was set to “Neural networks.” Proteins with a
D-score of 0.43 were then selected (16, 17). Third, secretory pro-
teins were also identified based on nonclassical secretion prediction
using SecretomeP 2.0 (28) as those with with an NN-score of 0.5
(16, 17). The DAVID software was used for functional enrichment
analysis (http://david.abcc.ncifcrf.gov/) for Gene Ontology biological
process (GOBP) and GOCC) A list of identified proteins was submit-
ted and analyzed using the following parameters: the count threshold
was set at 2, and the p value was set at 0.1 (a default cutoff) (16, 17).
Putative exosomal proteins were screened using the ExoCarta exo-
some database (29).
Cell-based Stimulation Experiments—Following differentiation, L6
myotubes and primary mouse skeletal muscle cells were treated
with 150 M palmitate for 18 h to induce insulin resistance as
described in the section detailing the “Cell culture and establish-
ment of insulin resistance.” The cells were cotreated with Ac2–26
(Anygen, Jangseong-gun, Jeonnam, Korea), WKYMVm (Trp-Lys-Tyr-
Met-Val-D-Met; Anygen, Korea), WRW4 (Trp-Arg-Trp-Trp-Trp-Trp;
Anygen), and palmitate for 18 h, depending on the experimental
conditions. Then the cells were treated with 100 nM insulin for 20 min,
and the cells were harvested.
Animal Experiments—All experimental procedures involving ani-
mals were approved by the POSTECH (Pohang University of Science
and Technology) Animal Use and Care Committee. C57BL/6J mice
(male, 6 weeks old) were kept under a 12-hour light/dark cycle with
free access to water. The mice received a 60% high-fat diet (HFD) for
10 weeks to induce insulin resistance, and the body weight of each
animal was monitored. WKYMVm was dissolved in a vehicle solution
consisting of 20% water and 80% saline. After 10 weeks of a HFD,
mice received intravenous injections of WKYMVm (200 g/head) or
vehicle daily for 5 days. For the glucose tolerance test (GTT), mice
subjected to an overnight fast were injected intraperitoneally with
glucose (1 g/kg). Blood was collected from the tail vein at 15, 30, 60,
and 120 min, and glucose levels were measured. The fasting and
feeding insulin levels were measured with an insulin ELISA kit
(ALPCO). For lipid profiling, mouse serum was obtained by clotting
the blood for 1 h, followed by centrifugation for 1 h at 2000 rpm.
Serum triglyceride, cholesterol, LDL cholesterol, and high-density
lipoprotein cholesterol were measured using an automatic chemistry
analyzer (BS-380; Mindray). To observe insulin signaling in metabolic
tissues, mice were fasted overnight; insulin was then injected intra-
peritoneally (5 units/kg) for 10 min. Phosphorylation of Akt in the
skeletal muscles, liver, and epididymal white adipose tissue (WAT)
was evaluated with Western blotting.
Statistical Analysis—All data were expressed as the mean  S.E.
All statistical analyses were performed using Student’s t test (two
groups) or one-way ANOVA (two groups). Tukey’s test or Tam-
hane’s T2 test was used for multiple comparisons. A p value of0.05
was considered significant.
(Experimental procedures for the GLUT4 translocation assay, the
MTT assay, RNA extraction, quantitative PCR analysis, PCR analysis,
and Western blot are presented in the supplemental Data).
RESULTS
Quantitative Proteomic Analysis of the Secretome of Palmi-
tate-induced Insulin Resistance—To find appropriate condi-
tions for palmitate-induced insulin resistance, we performed
the GLUT4 translocation assay using differentiated L6 rat
skeletal muscle cells treated with different concentrations of
palmitate for 18 h. We found that 150–300 M of palmitate
inhibited insulin-induced GLUT4 translocation with statistical
confidence (supplemental Fig. S1A). After measuring the cell
viability (supplemental Fig. S1B), we selected 150 M as the
optimal concentration for insulin resistance. Treatment with
150 M palmitate did not affect the morphology of L6 myo-
tubes (Fig. 1A). After stimulating the cells with palmitate, we
assessed the expression of pro-inflammatory cytokine genes,
such as TNF- and IL-6. The expression of TNF- and IL-6
increased under palmitate-treated conditions (Fig. 1B). To
examine the possible impairment of downstream insulin-in-
duced signaling after palmitate treatment, we used Western
blotting to monitor the phosphorylation of Akt, an important
signaling molecule in insulin stimulation. Insulin-induced
phosphorylation of Akt (S473) was markedly inhibited after
palmitate treatment (Fig. 1C).
For the secretome analysis, we collected and processed
conditioned media from palmitate-treated and nontreated
(NT) cells. The trypsin-digested peptides from the conditioned
medium were subjected to LC- electrospray ionization (ESI)-
MS/MS. We searched the combined rat/bovine IPI database
using the MASCOT search engine and identified 189 proteins
from NT and palmitate-treated conditions (Fig. 1D and sup-
plemental Table S1). We used APEX for label-free protein
quantification (26) and found that the abundances of 36 pro-
teins had changed (p value  0.05 and log2 change  0.58 ):
the levels of eight proteins were higher in the palmitate-
treated group than in the NT control, whereas those of 28
proteins were lower (supplemental Table S1). To select puta-
tive secretory proteins from among these proteins, we used a
previously reported approach that utilizes three separate
methods (16, 17). Among the 36 proteins modulated by palmi-
tate-induced insulin resistance, Gene Ontology selected 21
proteins, signal sequence prediction selected 25 proteins,
and nonclassical secretion prediction selected six proteins as
secretory proteins. Twelve exosomal proteins were screened
with the ExoCarta database. Thus, 36 proteins were selected
as secretory proteins modulated by palmitate-induced insulin
resistance (Table I).
To verify the quantitative results, we analyzed several rep-
resentative proteins secreted after palmitate treatment with
quantitative polymerase chain reaction (Q-PCR) and Western
blotting. Q-PCR analysis showed that the gene expression of
two secretory proteins, including heat shock protein beta-1
(Hspb1) and serpin H1 (Serpinh1), increased markedly; how-
ever, the level of collagen alpha-1(I) chain (Col1a1) decreased
(Fig. 1E). These results correlated with the results of the
LC-ESI-MS/MS analysis. Western blot analysis also showed
that the levels of two secretory proteins, matrix metalloprotei-
nase-2 (MMP-2) and annexin A1, decreased in the palmitate-
treated samples, a result that was also consistent with the
results of the LC-ESI-MS/MS analysis (Fig. 1F).
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Bioinformatic Analysis of Secretory Proteins Modulated by
Palmitate-induced Insulin Resistance—To identify the biolog-
ical features of the increased and decreased proteins, we
used the DAVID software (16, 17). Enrichment analysis of
GOBPs revealed that the increased proteins were involved in
cellular homeostasis, actin filament organization, and regula-
tion of apoptosis, whereas the decreased proteins were
involved in cell adhesion, extracellular matrix organization,
response to wounding, and regulation of cell growth (supple-
mental Fig. S2A). The analysis of GOCCs showed that, inter-
estingly, only the decreased proteins predominantly localized
to the extracellular region, whereas the increased proteins
predominantly localized to intracellular regions (supplemental
Fig. S2B). Additionally, we studied the secretory proteins us-
ing two recent reports that provided lists of known stress
proteins or proteins repeatedly identified in proteomic analy-
FIG. 1. Conditioned media preparation and quantitative proteomic analysis of the palmitate-induced insulin resistance secretome.
A, Microscopic images of differentiated L6 rat skeletal muscle cells. Sequential optical microscopy images indicate L6 rat skeletal muscle cells
after palmitate treatment. B, Q-PCR analysis of TNF- and IL-6. The y axis indicates fold change relative to the NT control. *, #p 0.05, between
NT and palmitate condition. C, Western blot of proteins that mediate insulin downstream signals. Conditioned cell lysates were electrophore-
sed and blotted. “Insulin” indicates 100 nM of insulin treatment for 20 min. D, Venn diagram of the 189 identified proteins. “NT” and “Pal”
indicate the control and palmitate-treated conditions, respectively. E, Q-PCR analysis of palmitate-modulated secretory proteins. The y axis
indicates the relative fold change against the NT control. F, Western blots of palmitate-modulated secretory proteins. The levels of MMP-2 and
annexin A1 decreased in the conditioned media of palmitate condition. “CM” indicates conditioned media from both conditions. “NT” and “Pal”
indicate the control and palmitate-treated conditions, respectively. The right graphs show densitometric analysis of MMP-2 and annexin A1.
Western blot results were densitometrically analyzed using ImageJ (ver. 1.38). All data in the figure are presented as mean  S.E., n  3–4
per group; *, #p  0.05, in the Student’s t test.
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ses (30, 31). We found that 62% of the increased secretory
proteins overlapped with the proteins in these lists, indicating
that they are stress proteins (supplemental Fig. S2C). In con-
trast, only 7% of the decreased secretory proteins were on
these lists. The bioinformatics results indicate a clear differ-
ence in the functional annotation pattern and biological char-
acteristics of the increased and decreased secretory proteins.
They also suggest that functional cytokine candidates are
present among the decreased proteins rather than among the
increased proteins.
Protective Role of Annexin A1 and its Receptor Agonist
(WKYMVm) in Palmitate-Induced Insulin Resistance in L6
Myotubes—From the results of the bioinformatics study, we
hypothesized that the group of decreased proteins included
functional cytokine candidates. In the proteomics study, we
found that annexin A1 decreased in the secretome of palmi-
tate-treated cells (Table I), and we confirmed that its secretion
was down-regulated in conditioned media (Fig. 1F). Further-
more, it has been reported that the plasma level of annexin A1
is down-regulated in obese patients (32). Recent reports on
the anti-inflammatory effect of annexin A1 and the relationship
between inflammation and insulin resistance (33) led us to
investigate the putative role of annexin A1 as a regulator of
insulin resistance in skeletal muscle. Because previous re-
ports have demonstrated that annexin A1 acts on an impor-
tant chemoattractant receptor, FPR2 (34, 35), we investigated
whether L6 skeletal muscle cells express the annexin A1
receptor. As shown in supplemental Fig. S3A, L6 skeletal
muscle cells expressed FPR2 at the mRNA level. Stimulation
of the cells with an N-terminal-derived active peptide of
annexin A1, Ac2–26, and a well-characterized FPR2 ago-
nist, WKYMVm, elicited ERK (extracellular signal-regulated
kinase) phosphorylation, indicating that L6 skeletal muscle
cells expressed the functional annexin A1 receptor, FPR2
TABLE I
List of secretory proteins modulated by Palmitate-induced insulin resistance. For “Filtering methods,” letters indicate how proteins were
identified as secretory: “G” indicates Gene Ontology, “C” indicates SignalP (Classical), “N” indicates SecretomeP (Nonclassical) and “E”
indicates ExoCarta (Exosome). “Fold change” indicates change of value of APEX for each protein between NT and Palmitate condition
Accession Name Filtering methods Fold change (log2) p value
IPI00958044.1 Histone cluster 1, H2ae-like N 1.59 0.0026
IPI00324741.3 Protein disulfide-isomerase A3 C,E 0.87 0.0000
IPI00230941.5 Vimentin N,E 0.83 0.0000
IPI00231260.5 Peroxiredoxin-6 E 0.73 0.0278
IPI00201586.1 Heat shock protein beta-1 N,E 0.72 0.0015
IPI00204703.5 Serpin H1 C 0.69 0.0002
IPI00231734.5 Fructose-bisphosphate aldolase A E 0.62 0.0003
IPI00327144.7 Cofilin-1 N,E 0.61 0.0362
IPI00188909.3 Collagen alpha-1(I) chain G,C 	0.59 0.0094
IPI00361798.2 Insulin-like growth factor binding protein 7 G,C 	0.70 0.0002
IPI00194566.1 Procollagen C-endopeptidase enhancer 1 G,C 	0.73 0.0000
IPI00207199.3 Connective tissue growth factor G,C 	0.73 0.0039
IPI00205807.1 Metalloproteinase inhibitor 2 G,C 	0.81 0.0002
IPI00197696.2 Malate dehydrogenase, mitochondrial E 	0.82 0.0000
IPI00231615.5 Annexin A1 G,E 	0.91 0.0149
IPI00189714.5 Collagen, type XII, alpha 1 G,N 	0.99 0.0238
IPI00476991.1 Neural cell adhesion molecule 1 C 	1.03 0.0000
IPI00191090.1 Biglycan G,C 	1.09 0.0000
IPI00194930.5 Glypican-1 G,C 	1.13 0.0000
IPI00204359.1 Beta-2-microglobulin G,C,E 	1.18 0.0000
IPI00188921.1 Collagen alpha-2(I) chain G,C 	1.19 0.0000
IPI00189424.2 SPARC G,C 	1.23 0.0000
IPI00191578.4 72 kDa type IV collagenase (MMP-2) G,C 	1.29 0.0009
IPI00326070.3 Cathepsin L1 G,C 	1.31 0.0000
IPI00205022.1 Nucleobindin-1 C 	1.38 0.0000
IPI00758468.2 Plasma glutamate carboxypeptidase G,C 	1.39 0.0014
IPI00206239.1 Insulin-like growth factor-binding protein 4 G,C 	1.43 0.0026
IPI00326433.11 10 kDa heat shock protein, mitochondrial N 	1.44 0.0236
IPI00197074.3 Dystroglycan 1 G,C 	1.56 0.0003
IPI00373753.5 Protein tyrosine kinase 7 E 	1.56 0.0001
IPI00411254.1 M-cadherin C 	1.60 0.0000
IPI00210920.1 Aspartate aminotransferase, mitochondrial C 	1.66 0.0001
IPI00364868.3 collagen, type XV, alpha 1 G,C 	1.72 0.0000
IPI00366944.2 Collagen alpha-1(III) chain G,C,E 	2.03 0.0000
IPI00200757.1 Isoform 1 of Fibronectin G,C,E 	2.37 0.0000
IPI00366945.3 collagen, type V, alpha 2 G,C 	2.43 0.0018
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(supplemental Fig. S3B and S3C). Insulin-induced Akt phos-
phorylation is a crucial component of insulin signaling. How-
ever, insulin-induced Akt phosphorylation was strongly inhib-
ited when cells were exposed to palmitate for 18 h (Fig. 2A).
When the cells were stimulated with Ac2–26 in the presence
of palmitate, palmitate-induced insulin resistance was mark-
edly reduced. Ac2–26 alone did not affect insulin-induced Akt
phosphorylation in the absence of palmitate. To determine if
FPR2 agonists in general have an inhibitory effect on palmi-
tate-induced insulin resistance, we tested the effect of the
FPR2 agonist WKYMVm in the system. In addition to Ac2–26,
WKYMVm strongly blocked palmitate-induced insulin resis-
tance, with increased levels of Akt phosphorylation observed
in the presence of palmitate (Fig. 2B). These results indicate
that the annexin A1-FPR2-mediated signaling pathway pro-
tects L6 myotubes from the palmitate-induced impairment of
downstream insulin signaling.
It has been reported that palmitate induces insulin resis-
tance through the phosphorylation of PKC- at T538 and
that phosphorylated PKC- induces IRS1 phosphorylation at
S307, as well as IL-6 expression (9). We further investigated
the involvement of the annexin A1-FPR2 axis in palmitate-
induced insulin resistance in L6 myotubes. We found that
Ac2–26 inhibited the phosphorylation of PKC- (T538) and
IRS1 (S307) in the presence of palmitate (Fig. 2C). The FPR2
agonist WKYMVm also inhibited the phosphorylation of
PKC- and IRS1 under the same conditions (Fig. 2D). We then
assessed the expression of IL-6, another downstream target
of PKC-. Both Ac2–26 and WKYMVm reduced IL-6 expres-
sion in L6 myotubes (Fig. 2E).
Next, using a well-characterized FPR2 antagonist, WRW4
(Trp-Arg-Trp-Trp-Trp-Trp) (36–38), we determined whether
modulation of FPR2 activity inhibits the protective effect of
WKYMVm. When cells were cotreated with WRW4 in the
presence of WKYMVm, the insulin-dependent phosphoryla-
tion of Akt was lower than after treatment with WKYMVm
alone (supplemental Fig. S4A). We then evaluated the effect of
WRW4 on the phosphorylation of PKC- (T538) and IRS1
(S307) in the presence of palmitate. We found that WRW4
treatment inhibited the WKYMVm-induced reduction in PKC-
(T538) and IRS1 (S307) phosphorylation (supplemental Fig.
S4B). We also assessed the protective effect of WKYMVm
in primary mouse skeletal muscle cells. Treatment with
WKYMVm blocked palmitate-induced insulin resistance; Akt
phosphorylation increased in the presence of palmitate (sup-
plemental Fig. S5A). WKYMVm also inhibited the phosphory-
lation of PKC- (T538) and IRS1 (S307) under the same con-
ditions (supplemental Fig. S5B). These results indicated that
modulation of FPR2 inhibited the protective effect of
WKYMVm on palmitate-induced insulin resistance. Collec-
tively, these findings suggest that the annexin A1-FPR2 axis
alters insulin resistance in skeletal muscle by modulating the
PKC- pathway.
Improvement of Insulin Sensitivity in High-fat Diet Mice after
Treatment with an FPR2 Agonist—We hypothesized that an-
nexin A1 plays a protective role in preventing insulin resis-
tance in the metabolically normal state. However, in obesity,
lower plasma levels of annexin A1 contribute to the develop-
ment of insulin resistance. Therefore, we expected that an-
nexin A1 would be involved in a relatively early stage of insulin
resistance. To investigate the in vivo role of annexin A1 in the
early stages of insulin resistance, we fed C57BL/6J mice a
HFD for 10 weeks. Body weight increased significantly, indic-
ative of an obese state (supplemental Fig. S6A). We measured
annexin A1 levels in the plasma as well as in the lysates of
skeletal muscle. The plasma level of annexin A1 was markedly
lower in HFD mice than in normal chow diet (NCD) mice (Fig.
3A). This result correlated with the quantitative secretomics
data obtained using palmitate-treated cells (Table I). The level
of annexin A1 in skeletal muscle was also down-regulated in
HFD mice (supplemental Fig. S6B). Because we identified a
protective role for the annexin A1-FPR2 axis in palmitate-
induced insulin resistance, we further characterized its effect
on whole-body insulin sensitivity in NCD and HFD mice. We
intravenously injected the FPR2 agonist WKYMVm into NCD
and HFD mice for 5 days and measured metabolic changes.
During the injection period, there was no significant change in
body weight (supplemental Fig. S6C). When we performed
GTTs (Fig. 3B), we noted a clear improvement in glucose
tolerance in HFD mice at 30 and 60 min following glucose
injection. The area under the curve (AUC) for the GTT also
decreased in the treatment groups (supplemental Fig. S7A).
The increase in fasting glucose level was not statistically
significant in HFD mice treated with the FPR2 agonist (Fig.
3C). The FPR2 agonist clearly reduced the fasting insulin level
in HFD mice (Fig. 3D), as well as the feeding glucose and
insulin levels (supplemental Fig. S7B and S7C).
Effects of the Annexin A1 Receptor Agonist on Metabolic
Tissues in HFD Mice—We further characterized the insulin
sensitizing effects of the annexin A1 receptor agonist on
metabolic tissues in HFD mice. The phosphorylation of PKC-
and IRS1 in skeletal muscle tissue was examined with West-
ern blot to determine whether the results were consistent with
those from L6 myotubes. Administration of the FPR2 agonist
reduced the phosphorylation of PKC- (T538) and IRS1 (S307)
in HFD mice (Fig. 4A). We further investigated whether admin-
istration of the FPR2 agonist improved insulin-stimulated Akt
phosphorylation in metabolic tissues. In the case of skeletal
muscle, insulin-stimulated Akt phosphorylation (S473) was
higher in HFD mice administered the FPR2 agonist than in
HFD mice administered vehicle alone (Fig. 4B). Insulin-stimu-
lated Akt phosphorylation in the liver also increased (for the
same comparison). However, there was no significant change
in Akt phosphorylation in WAT.
Insulin resistance is associated with a change in the cyto-
kine profile of WAT (39). Here, we compared the mRNA levels
of several important inflammatory cytokines, such as TNF-,
Metabolic Function of Annexin A1 as a Myokine
Molecular & Cellular Proteomics 14.4 887
 by guest on July 18, 2019
http://w
w
w
.m
cponline.org/
D
ow
nloaded from
 
FIG. 2. Protective role of annexin A1 and its receptor agonist, WKYMVm, on palmitate-induced insulin resistance of L6 myotubes. A,
Western blot of Akt phosphorylation after cotreatment with 150 M palmitate and 10 M Ac2–26. Conditioned cell lysates were electrophoresed
and blotted. The lower graph shows densitometric analysis of Akt phosphorylation. B, Western blot of Akt phosphorylation after cotreatment
with 150 M palmitate and 100 nMWKYMVm. Conditioned cell lysates were electrophoresed and blotted. The lower graph shows densitometric
analysis of Akt phosphorylation. “Insulin” indicates 100 nM of insulin treatment for 20 min. C, Western blot of PKC- and IRS1 phosphorylation
after cotreatment with 150 M palmitate and 10 M Ac2–26. Conditioned cell lysates were electrophoresed and blotted. The right graph shows
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IL-1, CCL2, and IL-4, in the WAT of HFD mice after admin-
istration of vehicle or FPR2 agonist (Fig. 4C). The mRNA ex-
pression of TNF-, IL-1, and CCL2 was down-regulated by
the FPR2 agonist. However, the level of IL-4 mRNA increased
in mice administered the FPR2 agonist. There were no signif-
icant changes in the mRNA levels of these cytokines in NCD
mice (supplemental Fig. S7D). In addition, we profiled repre-
sentative serum lipids, including triglyceride, cholesterol, LDL
cholesterol, and high-density lipoprotein cholesterol. There
were no significant differences between vehicle and WKYMVm
treatment (supplemental Fig. S8). These results indicate that the
FPR2 agonist WKYMVm improves insulin sensitivity in HFD
mice by sensitizing the insulin pathway in metabolic tissues,
including skeletal muscle and the liver, and by regulating inflam-
matory cytokine expression in WAT.
DISCUSSION
To our knowledge, this is the first proteomic study of con-
ditioned media following the development of palmitate-in-
duced insulin resistance in skeletal muscle. Using optimized
densitometric analysis of PKC- and IRS1 phosphorylation. D, Western blot of PKC- and IRS1 phosphorylation after cotreatment with 150 M
palmitate and 100 nM WKYMVm. Conditioned cell lysates were electrophoresed and blotted. The right graph shows densitometric analysis of
PKC- and IRS1 phosphorylation. Western blot results were densitometrically analyzed using ImageJ (ver. 1.38). E, Relative mRNA expression
of IL-6 after cotreatment with 150 M palmitate and 10 M Ac2–26 or 100 nM WKYMVm. The y-axis indicates the relative fold change against
the nontreated control. All data in the figure are presented as mean  S.E. n  3–5 per group; *p  0.05 in Student’s t test or in one-way
ANOVA.
FIG. 3. Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Mice were fed an NCD or HFD
for 10 weeks, and then treated with 200 g/head of WKYMVm or a vehicle control for 5 days. A, Western blot of annexin A1 in the plasma of
vehicle-treated NCD or HFD mice. The lower graph shows densitometric analysis of annexin A1. ANXA1 indicates annexin A1. B, Glucose
tolerance test for the treatment groups. *p  0.05, between HFD (Vehicle) and HFD (WKYMVm). C, Fasting plasma glucose concentrations in
each treatment group. *p  0.05, between NCD (Vehicle) and HFD (Vehicle). D, Fasting plasma insulin concentrations in each treatment group.
*p 0.05, between NCD (Vehicle) and HFD (Vehicle). #p 0.05, between HFD (Vehicle) and HFD (WKYMVm). All data in the figure are presented
as mean  S.E.; n  35 per group; *, #p  0.05, in Student’s t test or in one-way ANOVA.
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secretomic techniques, we identified 189 skeletal muscle-
derived proteins in the conditioned media. Using a reliable,
label-free quantitative method and a secretory protein filtering
method, we found 36 putative secretory proteins that were
modulated by palmitate-induced insulin resistance. We have
provided a list of new myokine candidates, which is valuable
information for designing further diabetes studies. We have also
identified biomarkers for obesity-induced insulin resistance. In
FIG. 4. Effects of the annexin A1 receptor agonist on metabolic tissues in HFD mice. Mice were fed an NCD or HFD for 10 weeks, and
then treated with 200 g/head of WKYMVm or a vehicle control for 5 days. A, Western blot of PKC- and IRS1 in skeletal muscle from HFD
mice administered the FPR2 agonist. Conditioned tissue lysates were electrophoresed and blotted. The right graph shows densitometric
analysis of PKC- and IRS1 phosphorylation. B, Western blot of Akt phosphorylation of metabolic tissues, including skeletal muscles, the liver,
and WAT, after intraperitoneal injection of insulin (5 U/kg) for 10 min. Conditioned tissue lysates were electrophoresed and blotted. The right
graph shows densitometric analysis of Akt phosphorylation. Western blot results were densitometrically analyzed using ImageJ (ver. 1.38). C,
Relative mRNA expression of inflammatory cytokines in the WAT of HFDmice: TNF-, IL-1, CCL2, and IL-4. All data in the figure are presented
as mean  S.E.; n  35 per group; *p  0.05, in Student’s t test or in one-way ANOVA.
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particular, we found that secretion of the myokine annexin A1
decreased under conditions that induced palmitate-induced
insulin resistance. Through subsequent cell and animal exper-
iments, we found that the annexin A1-FPR2 pathway played a
role in the palmitate-induced insulin resistance of L6 myo-
tubes, as well as in systemic insulin resistance.
Annexin A1, the first well-characterized member of the an-
nexin family, is a calcium-dependent phospholipid-binding
protein (40). Annexin A1 regulates diverse cellular processes,
including vesicle trafficking, cytoskeletal rearrangement, cell
migration, and inflammation (40). In skeletal muscle physiol-
ogy, annexin A1 promotes the migration of muscle satellite
cells, resulting in myoblast cell differentiation (41). The target
receptor for annexin A1, FPR2, an important classical che-
moattractant receptor, mediates leukocyte recruitment and
anti-inflammatory effects induced by an N-terminal-derived
peptide of annexin A1, Ac2–26 (33). Although the plasma level
of annexin A1 is down-regulated in obese patients (32), its
metabolic function as a cytokine and its mode of action have
not been characterized. Here, we describe a putative role for
annexin A1 in the insulin resistance of skeletal muscle cells.
Annexin A1 and WKYMVm, which act on the same receptor,
FPR2, strongly blocked palmitate-induced insulin resistance,
restoring insulin-induced signaling in vitro. WKYMVm amelio-
rated HFD-induced insulin resistance in mice. Annexin A1 is
involved in the anti-inflammatory pathway and is down-regu-
lated in the plasma of obese patients (32, 33). We have also
reported that the annexin A1 level decreases in the myotube
secretome of TNF--induced insulin resistance (17). Consid-
ering these findings, it is possible that the secretion of annexin
A1 decreases in major cases of insulin resistance involving
inflammation and hyperlipidemia. As a novel myokine, an-
nexin A1 might serve as an auto/endocrine mediator that
regulates insulin resistance.
Here, we showed that activation of FPR2 improves key
metabolic features in HFD mice. This effect was observed
only in the HFD condition, not in the NCD condition. Further-
more, activation of FPR2 inhibited proinflammatory cytokines
and induced anti-inflammatory cytokines in WAT. Thus, acti-
vation of FPR2 in HFD mice reversely regulates whole-body
inflammation, which is a well-known cause of metabolic dis-
ease. In support of this idea, it was previously reported that
FPR2-knockout mice show signs of marked inflammation,
including increased cell adherence and emigration in the mes-
enteric microcirculation following an ischemia-reperfusion in-
sult, and an augmented acute response to carrageenan-in-
duced paw edema (34). To understand the function of annexin
A1 as a myokine, the use of conditional mouse models, such
as skeletal muscle-specific knockout mice, will be important
for future work.
According to the series of bioinformatic studies shown in
Fig. 2, the functional annotation features of proteins that
increased and decreased differed. It has been reported that
palmitate-induced cellular stress is mediated by a well-known
pathway, including the diacylglycerol-PKC-NF-B axis (42–
45). We found that approximately half of the increased
proteins were stress proteins. This indicates that palmitate
treatment induces cellular stress and the secretion of stress-
related proteins. In contrast, the decreased proteins were
annotated as extracellular proteins, and they included fewer
stress proteins. This suggests that palmitate-induced insulin
resistance affects the secretion of candidate myokines, par-
ticularly those whose secretion was reduced. The results also
validated our experimental set-up by showing that palmitate
induces insulin resistance through cellular stress.
In conclusion, we used a reliable and optimized proteomic
approach to identify myokine candidates produced by skele-
tal muscle in response to palmitate-induced insulin resis-
tance. We found that annexin A1 secretion was down-regu-
lated and that the annexin A1-FPR2 pathway played a
protective role in palmitate-induced insulin resistance in L6
myotubes by modulating the PKC- pathway. Treatment of
HFD mice with the FPR2 agonist significantly improved
whole-body insulin sensitivity by sensitizing the insulin path-
way in metabolic tissues, including skeletal muscle and the
liver, and by regulating inflammatory cytokine expression in
WAT. Thus, the annexin A1-FPR2 axis might be a new ther-
apeutic target for insulin resistance.
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